Post Metabolic Fatloss Comparison

Metabolic dysregulation — encompassing obesity, insulin resistance, dyslipidemia, and visceral adiposity — is among the most researched targets in contemporary peptide science. Exceed Enhancement stocks several compounds with distinct mechanisms for studying fat metabolism and body composition: AOD-9604 (a GH fragment), 5-Amino-1MQ (an NNMT inhibitor), Cagrilintide (an amylin analog), and the GLP receptor agonists (GLP-1 S, GLP-2 T, GLP-3 R). While all intersect with energy balance and fat metabolism, they do so through substantially different pathways — making them complementary tools for multi-mechanism metabolic research. This guide compares them systematically. All content is for scientific and educational purposes only.

AOD-9604 (Anti-Obesity Drug 9604)

Structure and Origin

AOD-9604 is a synthetic peptide fragment corresponding to amino acids 176–191 of the C-terminus of human growth hormone (hGH), with a tyrosine residue added to the N-terminus to improve bioavailability. It was originally developed by Metabolic Pharmaceuticals in Australia specifically to isolate the lipolytic activity of growth hormone — separating fat metabolism effects from GH’s anabolic (muscle growth), diabetogenic (insulin resistance), and proliferative effects.

Primary Mechanism

AOD-9604 was designed to mimic the fat-metabolizing region of GH without activating the full GH receptor (GHR). Its proposed mechanism centers on direct interaction with β3-adrenergic receptors and modulation of lipid metabolism in adipocytes — stimulating lipolysis (fat breakdown) and inhibiting lipogenesis (fat synthesis) independently of IGF-1 signaling. Unlike exogenous GH, AOD-9604 does not raise IGF-1 levels, does not cause insulin resistance, and does not stimulate cell proliferation — making it a cleaner model for studying fat-specific GH biology.

In rodent models, AOD-9604 has demonstrated reductions in body fat in obese animals through lipolysis stimulation in white adipose tissue. It has also shown activity in promoting fat oxidation in brown adipose tissue — relevant to thermogenesis research.

Clinical Development and Status

AOD-9604 advanced to Phase IIb/III human clinical trials for obesity treatment but did not meet primary endpoints for statistically significant weight loss versus placebo in a large 12-week trial. Subsequent research has continued in joint health applications — AOD-9604 demonstrated cartilage-regenerating properties in preclinical models, and it received FDA designation as a Generally Recognized as Safe (GRAS) food substance. This unusual regulatory history makes it one of the more extensively safety-profiled research peptides available.

Primary Research Applications

• Adipocyte lipolysis and lipogenesis inhibition
• GH fragment biology — isolating fat metabolism from anabolic GH effects
• Brown adipose tissue thermogenesis
• Cartilage repair and joint health (secondary application)
• Obesity models without IGF-1 or insulin confounds

5-Amino-1MQ (5-Amino-1-Methylquinolinium)

Structure and Discovery

5-Amino-1MQ is a small molecule (not a peptide — a methylquinolinium compound) that is a potent and selective inhibitor of nicotinamide N-methyltransferase (NNMT) — an enzyme that methylates nicotinamide (a form of vitamin B3) to produce 1-methylnicotinamide, consuming S-adenosylmethionine (SAM) in the process. NNMT is highly expressed in white adipose tissue and liver in obese individuals, and its overexpression is associated with insulin resistance and metabolic dysfunction. 5-Amino-1MQ was identified through drug discovery efforts specifically targeting NNMT as a novel anti-obesity enzyme target.

Primary Mechanism

NNMT inhibition → SAM preservation → polyamine flux and NAD+ restoration: By blocking NNMT, 5-Amino-1MQ preserves SAM — the universal methyl donor — and redirects it away from nicotinamide methylation. This has several downstream consequences in adipocytes:

• NAD+ regeneration: NNMT consumes nicotinamide that could otherwise be recycled to NAD+. Inhibiting NNMT raises cellular NAD+ — activating SIRT1 and other sirtuins, mimicking aspects of caloric restriction
• Polyamine biosynthesis: Preserved SAM fuels the polyamine pathway — increasing spermidine and spermine in adipocytes. Polyamines are essential for normal adipocyte differentiation but elevated in the context of NNMT inhibition they appear to redirect adipocyte metabolism toward a less lipogenic phenotype
• Adipocyte size reduction: In preclinical studies, NNMT inhibition with 5-Amino-1MQ reduced adipocyte hypertrophy — fat cell size — without reducing fat cell number, suggesting a qualitative improvement in adipose tissue biology

In vivo results: In diet-induced obese mice, 5-Amino-1MQ administration reduced body weight, visceral fat mass, plasma cholesterol, triglycerides, and insulin resistance without changes to food intake — suggesting improved metabolic efficiency rather than appetite suppression as the primary mechanism. This distinguishes it from GLP-based approaches that primarily reduce food intake.

Primary Research Applications

• NNMT inhibition and epigenetic/metabolic regulation in adipose tissue
• NAD+/sirtuin axis modulation (complementary to direct NAD+ supplementation)
• Visceral adiposity reduction without appetite suppression
• Insulin resistance and metabolic syndrome models
• Adipocyte biology and fat cell differentiation research

Cagrilintide (CagriSema partner / Amylin Analog)

Structure and Origin

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk. Amylin (islet amyloid polypeptide / IAPP) is an endogenous peptide co-secreted with insulin from pancreatic beta cells in response to meals. It acts centrally and peripherally to suppress glucagon, slow gastric emptying, and induce satiety — acting as a complementary satiety signal to insulin. Cagrilintide is engineered with fatty acid conjugation for albumin binding (similar to semaglutide’s mechanism for half-life extension), enabling once-weekly dosing in clinical research settings.

Primary Mechanism

Amylin receptor (CALCR/RAMP) agonism: Cagrilintide activates amylin receptors — heterodimers of calcitonin receptor (CALCR) and receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3) expressed in the hypothalamus (area postrema, nucleus accumbens, hypothalamic nuclei) and peripheral tissues. Amylin receptor activation in the brain produces:

• Satiety signaling: Suppression of food intake through hypothalamic energy balance circuits — but via different neural pathways than GLP-1 receptor agonists (which primarily act via vagal afferents and NTS/PVN). Amylin signaling through area postrema projects to the lateral parabrachial nucleus — a distinct satiety circuit from GLP-1 R’s canonical pathway
• Glucagon suppression: Postprandial glucagon reduction, complementary to GLP-1’s glucagon-suppressing effects, improving postprandial glucose control
• Gastric emptying delay: Slowing of gastric emptying rate — reducing postprandial glucose excursions and extending satiety

Synergy with GLP-1 agonists — the CagriSema rationale: Cagrilintide’s most significant research application is in combination with semaglutide (GLP-1 RA) as “CagriSema” — Novo Nordisk’s combination formulation in Phase III trials. The rationale is mechanistic complementarity: GLP-1 RA and amylin agonism activate distinct satiety pathways, and their combination produces greater weight loss than either alone in clinical trials (up to ~22% body weight reduction at 68 weeks in Phase II). This combination strategy is a major focus of next-generation obesity pharmacotherapy research.

Primary Research Applications

• Amylin receptor biology and central satiety signaling
• Combination anti-obesity therapy research (amylin + GLP-1 synergy)
• Glucagon suppression and postprandial glycemia
• Long-acting amylin analog pharmacokinetics
• Beta cell biology and co-secretion modeling

GLP Receptor Agonists: GLP-1 S, GLP-2 T (Tirzepatide), GLP-3 R (Retatrutide)

The GLP peptide class in Exceed Enhancement’s catalog spans three generations of incretin-based research — each adding receptor targets and metabolic breadth beyond the previous:

GLP-1 S (Semaglutide — GLP-1 Receptor Agonist)

Semaglutide is a GLP-1 receptor (GLP-1R) agonist — a fatty-acid-conjugated GLP-1 analog with ~168-hour half-life enabling once-weekly research dosing. GLP-1R activation in the CNS (NTS, vagal afferents, hypothalamus) and pancreas produces: satiety and reduced food intake, glucose-dependent insulin secretion, glucagon suppression, and slowed gastric emptying. Semaglutide (Ozempic, Wegovy) is the most clinically validated weight loss peptide currently available — producing ~15% mean body weight reduction in clinical trials. It is the reference GLP-1 agonist against which newer compounds are compared.

GLP-2 T (Tirzepatide — GLP-1R + GIPR Dual Agonist)

Tirzepatide adds GIP receptor (GIPR) co-agonism to GLP-1R activity, creating a dual incretin agonist. GIPR activation in adipose tissue directly promotes lipolysis, reduces lipid storage, and may enhance GLP-1R-driven satiety signaling synergistically. The combination of GLP-1R + GIPR produces superior weight loss versus GLP-1R agonism alone — tirzepatide achieved ~20% body weight reduction in Phase III trials (SURMOUNT-1), outperforming semaglutide. It is FDA-approved as Mounjaro (T2D) and Zepbound (obesity). The GIP receptor component makes tirzepatide uniquely interesting for adipose tissue biology research that goes beyond classic GLP-1 pathway modulation.

GLP-3 R (Retatrutide — GLP-1R + GIPR + Glucagon Receptor Triple Agonist)

Retatrutide extends the dual agonist platform to full triple agonism — adding glucagon receptor (GCGR) activation to GLP-1R and GIPR. Glucagon receptor agonism in the liver increases hepatic fat oxidation, stimulates thermogenesis, and elevates energy expenditure — addressing the energy expenditure side of energy balance that GLP-1R agonists alone do not substantially engage. In Phase II trials, retatrutide produced the largest weight loss of any peptide studied to date — approximately 24% body weight reduction at 48 weeks — by combining appetite suppression (GLP-1R/GIPR) with enhanced energy expenditure (GCGR). It is currently in Phase III development. The glucagon agonism also makes it particularly relevant for hepatic steatosis (fatty liver) research, where glucagon receptor activation accelerates hepatic lipid clearance.

Head-to-Head Comparison

Mechanistic Complementarity for Research Design

These compounds target fat metabolism at different nodes — offering meaningful options for multi-mechanism research designs:

• AOD-9604 is the only compound in this group that directly targets peripheral adipocyte lipolysis via a GH-fragment mechanism — valuable when the research question concerns GH’s fat metabolism pathway specifically, isolated from anabolic GH effects
• 5-Amino-1MQ is the only NNMT inhibitor — uniquely relevant for research on epigenetic and enzymatic regulation of adipocyte metabolism, NAD+/sirtuin biology in fat tissue, and insulin sensitization without appetite suppression confounds
• Cagrilintide is the only amylin pathway agent — essential for research specifically modeling the amylin satiety circuit, or for studying the mechanistic basis of GLP-1 + amylin combination therapy superiority
• GLP-1 S, GLP-2 T, GLP-3 R represent a progressive receptor-addition series — allowing research to dissect the incremental contributions of GIP co-agonism (Tirz vs. Sema) and glucagon co-agonism (Reta vs. Tirz) to observed metabolic outcomes

Storage Notes

• AOD-9604, Cagrilintide, GLP-1 S, GLP-2 T, GLP-3 R: Lyophilized peptides — store at −20°C; reconstitute with bacteriostatic water; refrigerate after reconstitution, use within 30 days
• 5-Amino-1MQ: Small molecule — store in airtight container at room temperature or 2–8°C; protect from light and moisture; not a peptide, does not require peptide-specific reconstitution protocols

Disclaimer

All compounds described are sold strictly for in vitro and preclinical research purposes. GLP-1 S (semaglutide) and GLP-2 T (tirzepatide) exist as FDA-approved pharmaceutical products for specific clinical indications; the research-grade compounds described here are not equivalent to those approved formulations and are not intended for human therapeutic use. This content is for scientific and educational purposes only.

References

• Heffernan M, et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knockout mice. Endocrinology, 142(12), 5182–5189.
• Hong S, et al. (2021). Inhibition of nicotinamide N-methyltransferase reverses diet-induced obesity with an unexpected decrease in physical activity. Nature Metabolism, 3(9), 1258–1274.
• Enebo LB, et al. (2021). Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide. The Lancet, 397(10286), 1736–1748.
• Jastreboff AM, et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216.
• Jastreboff AM, et al. (2023). Triple-hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. New England Journal of Medicine, 389(6), 514–526.
• Drucker DJ. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351.